CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...
Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...
The MarketWatch News Department was not involved in the creation of this content. -- Financing led by US life sciences investor, BroadOak Capital Partners -- Investment to support expansion of US ...
Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, today announced that it has acquired the ophthalmology business of ...
Axol Bioscience, a biotechnology company, specialising in the use of stem cell technology to manufacture disease relevant cell based assay systems to the drug discovery industry, has announced Prof ...
CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd, an established provider of iPSC-derived cells, media, and characterization services, and CENSO Biotechnologies, a cell biology CRO with ...
The relationship brings together Horizon’s precision genome editing capability and Axol’s expertise in iPSC reprogramming and differentiation to provide isogenic cell lines for neuronal and ...
Provider of iPSC-derived cells, media, and characterization services, Axol Bioscience, has signed a merger agreement with Censo Biotechnologies, a cell biology CRO. Provider of induced pluripotent ...
Axol Bioscience Ltd. (Axol), a leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, today announced that it has secured $2.8 million (£2.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results